AuerbachMBallardH. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program2010;2010:338–347.
RodgersGMBeckerPSBlinderM. NCCN Clinical Practice Guidelines in Oncology: Cancer- and Chemotherapy-Induced Anemia Version 22012. Available at: NCCN.org. Accessed February 20 2012.
HenryDHDahlNVAuerbachMA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol2012;87:308–310.
KhoranaAAFrancisCWBlumbergN. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med2008;168:2377–2381.
AuerbachMBallardHTroutJR. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol2004;22:1301–1307.
RizzoJDBrouwersMHurleyP. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol2010;28:4996–5010.
MhaskarRWaoHKumarA. Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients: a systematic review and meta-analysis [abstract]. Blood2010;116(Suppl):Abstract 2055.
HenryDHDahlNVAuerbachM. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist2007;12:231–242.
HessGNordykeRJHillJHulnickS. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. Am J Hematol2010;85:838–843.
VekemanFBookhartBKWhiteJ. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion2009;49:895–902.
ShanderASpenceRKAuerbachM. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?Transfusion2010;50:719–732.
SinhaSChiuDPeeblesG. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients. QJM2011;104:221–230.
AuerbachMWinchesterJWahabA. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis1998;31:81–86.
KoutroubakisIEOustamanolakisPKarakoidasC. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci2010;55:2327–2331.
LowCBailieGEiseleG. Changes in hematocrit, serum ferritin and transferrin saturation after intravenous iron dextran [abstract]. J Am Soc Nephrol1996;7:Abstract 1392.
BastitLVandebroekAAltintasS. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol2008;26:1611–1618.
PedrazzoliPFarrisADel PreteS. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol2008;26:1619–1625.
HedenusMBirgegårdGNäsmanP. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia2007;21:627–632.
LooMBeguinY. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood1999;93:3286–3293.
GrossSKeeferVNewmanAJ. The platelets in iron-deficiency anemia. I. The response to oral and parenteral iron. Pediatrics1964;34:315–323.
PeeblesGStanleyS. Evaluation of service reconfiguration for managing intravenous iron supplementation in non-hemodialysis patients with chronic renal failure. Journal of Outcomes Research2004;8:15–25.
FletesRLazarusJMGageJChertowGM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis2001;37:743–749.
ChertowGMMasonPDVaage-NilsenOAhlmenJ. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant2005;21:378–382.
BartonJCBartonEHBertoliLF. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med2000;109:27–32.
LamanCASilversteinSBRodgersGM. Parenteral iron therapy: a single institution’s experience over a 5-year period. J Natl Compr Canc Netw2005;3:791–795.
YamadaYShigetomiHOnogiA. Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer2011;21:1200–1207.
WuTSemposCTFreudenheimJL. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol2004;14:195–201.
ZacharskiLRChowBKHowesPS. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst2008;100:996–1002.
KatoJMiyanishiKKobuneM. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol2007;42:830–836.
GutteridgeJMRowleyDAHalliwellB. Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of “catalytic” iron and anti-oxidant activity in extracellular fluids. Biochem J1982;206:605–609.
RamakrishnaGRookeTWCooperLT. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. Vasc Med2003;8:203–210.
DrüekeTBLocatelliFClyneN. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med2006;355:2071–2084.
BesarabABoltonWKBrowneJK. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med1998;339:584–590.
AuerbachMPappadakisJABahrainH. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol2011;86:860–862.
SteensmaDPSloanJADakhilSR. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol2011;29:97–105.
NakanishiTKuraganoTNanamiM. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol2010;32:439–446.